BAXTER 0.15% POTASSIUM CHLORIDE AND 0.225% SODIUM CHLORIDE AND 3.75% GLUCOSE 500mL injection BP אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

baxter 0.15% potassium chloride and 0.225% sodium chloride and 3.75% glucose 500ml injection bp

baxter healthcare pty ltd - glucose, quantity: 37.5 g/l; sodium chloride, quantity: 2.25 g/l; potassium chloride, quantity: 1.5 g/l - injection, intravenous infusion - excipient ingredients: water for injections - the potassium chloride ( 0.15%) and sodium chloride (0.225 %) and glucose (3.75 %) intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium, potassium and chloride ions in the body fluids. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

BAXTER 0.15% Potassium Chloride and 0.18% SODIUM CHLORIDE and 4% GLUCOSE 1000mL injection BPAHB1704 אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

baxter 0.15% potassium chloride and 0.18% sodium chloride and 4% glucose 1000ml injection bpahb1704

baxter healthcare pty ltd - potassium chloride, quantity: 1.5 g/l; sodium chloride, quantity: 1.8 g/l; glucose, quantity: 40 g/l - injection, solution - excipient ingredients: water for injections - the potassium chloride ( 0.15%) and sodium chloride (0.18 %) and glucose (4 %) intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium, potassium and chloride ions in the body fluids. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

BAXTER 0.244% POTASSIUM CHLORIDE and 0.18% SODIUM CHLORIDE and 4% GLUCOSE 1000mL injection AHB1224 אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

baxter 0.244% potassium chloride and 0.18% sodium chloride and 4% glucose 1000ml injection ahb1224

baxter healthcare pty ltd - glucose, quantity: 40 g/l; potassium chloride, quantity: 2.24 g/l; sodium chloride, quantity: 1.8 g/l - injection, solution - excipient ingredients: water for injections - the potassium chloride (0.224%), sodium chloride (0.18%), and glucose (4%) intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium, potassium and chloride ions in the body fluids. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

BUPIVACAINE-BAXTER bupivacaine hydrochloride (as monohydrate) 50 mg/10 mL solution for injection vial אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

bupivacaine-baxter bupivacaine hydrochloride (as monohydrate) 50 mg/10 ml solution for injection vial

baxter healthcare pty ltd - bupivacaine hydrochloride, quantity: 5 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 5.28 mg/ml) - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; sodium hydroxide; water for injections - indications ,bupivacaine-baxter is indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: ,surgical anaesthesia ,epidural block for surgery ,field block (minor and major nerve blocks and infiltration). ,analgesia ,continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. ,field block (minor nerve block and infiltration).

BUPIVACAINE-BAXTER bupivacaine hydrochloride (as monohydrate) 50 mg/20 mL solution for injection vial אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

bupivacaine-baxter bupivacaine hydrochloride (as monohydrate) 50 mg/20 ml solution for injection vial

baxter healthcare pty ltd - bupivacaine hydrochloride, quantity: 2.5 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 2.64 mg/ml) - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium chloride; sodium hydroxide - indications ,bupivacaine-baxter is indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: ,surgical anaesthesia ,epidural block for surgery ,field block (minor and major nerve blocks and infiltration). ,analgesia ,continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. ,field block (minor nerve block and infiltration).

Adenosine Baxter ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

adenosine baxter

baxter healthcare ltd - adenosine 3 mg/ml;  ;   - solution for infusion - 30 mg/10ml - active: adenosine 3 mg/ml     excipient: sodium chloride water for injection - intravenous adenosine baxter 30 mg/10 ml is a coronary vasodilator for use in conjunction with radionuclide myocardial perfusion imaging, in patients unable to exercise adequately.

Milrinone-Baxter ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

milrinone-baxter

baxter healthcare ltd - milrinone lactate 1.43 mg/ml equivalent to milrinone 1 mg/ml - concentrate for injection - 1 mg/ml - active: milrinone lactate 1.43 mg/ml equivalent to milrinone 1 mg/ml excipient: glucose lactic acid sodium hydroxide water for injection - milrinone-baxter is indicated for the short term intravenous therapy of severe congestive heart failure. the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics.

BAXTER POTASSIUM CHLORIDE 40 mmol and 0.9% SODIUM CHLORIDE 1000 mL intravenous infusion bag אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

baxter potassium chloride 40 mmol and 0.9% sodium chloride 1000 ml intravenous infusion bag

baxter healthcare pty ltd - potassium chloride, quantity: 2.98 g/l; sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.

BAXTER RINGERS SOLUTION injection 1000mL AHB2304 אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

baxter ringers solution injection 1000ml ahb2304

baxter healthcare pty ltd - sodium chloride, quantity: 8.6 g/l; calcium chloride dihydrate, quantity: 330 mg/l; potassium chloride, quantity: 300 mg/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - for restoring the loss of water and electrolytes as required by the clinical condition of the patient.

BORTEZOMIB BAXTER bortezomib 3.5 mg powder for injection vial אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

bortezomib baxter bortezomib 3.5 mg powder for injection vial

baxter healthcare pty ltd - bortezomib, quantity: 3.5 mg - injection, powder for - excipient ingredients: mannitol; nitrogen - bortezomib baxter, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,bortezomib baxter, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,bortezomib baxter is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.,bortezomib baxter in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.